Furthermore, EGFR mutations were linked to a lower tumor mutational burden (TMB) in comparison to wild-type EGFR, offering a scientific justification and a possible explanation for this subgroup’s poor immunotherapy response [92]. Here, EGFR is linked to neoplasm.